Consolidated Statements of Shareholders' Equity - USD ($)		Common Stock [Member]		Common Stock Subscribed [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016		83,964,569
Balance at Dec. 31, 2016		$ 10,189,973			$ 1,205,456	$ (7,561,028)	$ 3,834,401
Stock issuance for services (in shares)	[1],[2]	155,927
Stock issuance for services		$ 275,131	[1],[2]				275,131
Stock-based compensation					849,679		849,679
Stock issuance for financing, net of cost (in shares)	[3],[4]	4,405,373
Stock issuance for financing, net of cost		$ 6,513,424	[3],[4]				$ 6,513,424
Stock issued due to exercise of options (in shares)		1,700,000					1,700,000
Stock issued due to exercise of options		$ 1,266,131			(286,609)		$ 979,522
Net loss						(8,065,072)	(8,065,072)
Balance (in shares) at Dec. 31, 2017		90,225,869
Balance at Dec. 31, 2017		$ 18,244,659			1,768,526	(15,626,100)	4,387,085
Common Stock, Value, Subscriptions
Stock issuance for services (in shares)	[5],[6]	3,207,506
Stock issuance for services		$ 5,651,671	[5],[6]				5,651,671
Stock-based compensation					7,288		7,288
Stock issuance for financing, net of cost (in shares)	[7]	1,861,627
Stock issuance for financing, net of cost		$ 3,944,336	[7]				$ 3,944,336
Stock issued due to exercise of options (in shares)		2,303,896					2,303,896
Stock issued due to exercise of options		$ 2,569,982			(535,675)		$ 2,034,307
Net loss						(16,647,687)	(16,647,687)
Balance (in shares) at Dec. 31, 2018		97,598,898
Balance at Dec. 31, 2018		$ 30,410,648		4,280,000	1,240,139	(32,273,787)	3,657,000
Common Stock, Value, Subscriptions				$ 4,280,000			$ 4,280,000

[1] On December 22, 2017, the Company issued 112,314 common shares in accordance with a License and Supply Agreement with Celsee, Inc. and recognized $230,131 as a research and development expense in the consolidated statements of operations and comprehensive loss.

[2] On March 14, 2017, the Company settled $50,000 of amounts due to a vendor by issuing 43,613 common shares valued at $45,000 at the date of issuance. The Company recorded a $5,000 gain on the settlement of liabilities.

[3] On April 7, 2017, the Company issued 2,902,682 common shares for gross proceeds of $3,250,000. The Company recorded $32,754 of share issuance costs as an offset to capital stock.

[4] On July 28, 2017, the Company issued 1,502,691 common shares for gross proceeds of $3,320,000. The Company recorded $23,822 of share issuance costs as an offset to capital stock.

[5] On May 10, 2018, the Company issued 641,717 common shares in accordance with a Development, Commercialization and Exclusive Distribution Agreement with Seraph Biosciences, Inc. and recognized $1,238,513 as a research and development expense in the consolidated statements of operations and comprehensive loss.

[6] On November 26, 2018, the Company issued 2,565,789 common shares in accordance with a Development and Supply Agreement with Qorvo Biotechnologies, LLC and recognized $4,413,158 as a research and development expense in the consolidated statements of operations and comprehensive loss.

[7] On May 15, 2018, the Company issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, the Company issued 1,605,812 common shares for gross proceeds of $3,452,496. The Company recorded $58,160 of share issuance costs as an offset to capital stock.